Pfizer abandons research into Alzheimer’s and Parkinson’s diseases
BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k122 (Published 09 January 2018) Cite this as: BMJ 2018;360:k122- Nigel Hawkes
- London, UK
The drug giant Pfizer has announced that it is pulling out of early stage research into Alzheimer’s and Parkinson’s diseases, with the loss of 300 jobs.
Its money can be more productively invested elsewhere, the company said. “This was an exercise to reallocate spend across our portfolio, to focus on those areas where our pipeline, and our scientific expertise, is strongest,” it said. The job losses will be at sites in the US.
Mikael Dolsten, president of worldwide research and development for the company, told a conference in San Francisco on 8 January …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.